The Anticancer Effects of Marine Carotenoid Fucoxanthin through Phosphatidylinositol 3-Kinase (PI3K)-AKT Signaling on Triple-Negative Breast Cancer Cells
暂无分享,去创建一个
[1] K. Soliman,et al. Anticancer Effects of Fucoxanthin through Cell Cycle Arrest, Apoptosis Induction, and Angiogenesis Inhibition in Triple-Negative Breast Cancer Cells , 2023, Molecules.
[2] M. Pan,et al. Combination of FAK inhibitor and cytokine-induced killer cell therapy: An alternative therapeutic strategy for patients with triple-negative breast cancer. , 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[3] K. Soliman,et al. Anticancer Effects of Fucoxanthin through Cell Cycle Arrest, Apoptosis Induction, Angiogenesis Inhibition, and Autophagy Modulation , 2022, International journal of molecular sciences.
[4] Claire E. Tocheny,et al. The Insulin-like Growth Factor Signaling Pathway in Breast Cancer: An Elusive Therapeutic Target , 2022, Life.
[5] Long Chen,et al. Advances in Fucoxanthin Research for the Prevention and Treatment of Inflammation-Related Diseases , 2022, Nutrients.
[6] C. Shao,et al. TNFα and IFNγ rapidly activate PI3K-AKT signaling to drive glycolysis that confers mesenchymal stem cells enhanced anti-inflammatory property , 2022, Stem Cell Research & Therapy.
[7] L. Jia,et al. Fucoxanthin prevents breast cancer metastasis by interrupting circulating tumor cells adhesion and transendothelial migration , 2022, Frontiers in Pharmacology.
[8] I. V. Ogungbe,et al. Carotenoids in Drug Discovery and Medicine: Pathways and Molecular Targets Implicated in Human Diseases , 2022, Molecules.
[9] T. Boggon,et al. SH3 domain regulation of RhoGAP activity: Crosstalk between p120RasGAP and DLC1 RhoGAP , 2022, Nature Communications.
[10] Zunnan Huang,et al. Fucoxanthin Inactivates the PI3K/Akt Signaling Pathway to Mediate Malignant Biological Behaviors of Non-Small Cell Lung Cancer , 2022, Nutrition and cancer.
[11] Tariq Ahmad Masoodi,et al. Targeting cancer signaling pathways by natural products: Exploring promising anti-cancer agents. , 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[12] M. Muchtaridi,et al. Signaling Pathways and Natural Compounds in Triple-Negative Breast Cancer Cell Line , 2022, Molecules.
[13] H. Kwan,et al. Fucoxanthin Is a Potential Therapeutic Agent for the Treatment of Breast Cancer , 2022, Marine drugs.
[14] Md. Abdul Hannan,et al. A Systematic Review on Marine Algae-Derived Fucoxanthin: An Update of Pharmacological Insights , 2022, Marine drugs.
[15] Liangke Zhang,et al. Promoting Apoptosis, a Promising Way to Treat Breast Cancer With Natural Products: A Comprehensive Review , 2022, Frontiers in Pharmacology.
[16] Weilin Wang,et al. ELK1 Enhances Pancreatic Cancer Progression Via LGMN and Correlates with Poor Prognosis , 2021, Frontiers in Molecular Biosciences.
[17] Kui-Sheng Chen,et al. Targeting PI3K/Akt signal transduction for cancer therapy , 2021, Signal Transduction and Targeted Therapy.
[18] S. Volinia,et al. The Motility and Mesenchymal Features of Breast Cancer Cells Correlate with the Levels and Intracellular Localization of Transglutaminase Type 2 , 2021, Cells.
[19] Shile Huang,et al. Deficiency of eIF4B Increases Mouse Mortality and Impairs Antiviral Immunity , 2021, Frontiers in Immunology.
[20] E. Castellano,et al. The Importance of Being PI3K in the RAS Signaling Network , 2021, Genes.
[21] Xiang Xu,et al. TNF-α augments CXCL10/CXCR3 axis activity to induce Epithelial-Mesenchymal Transition in colon cancer cell , 2021, International journal of biological sciences.
[22] P. Foden,et al. FAK inhibition alone or in combination with adjuvant therapies reduces cancer stem cell activity , 2021, NPJ breast cancer.
[23] D. Purwaningsari,et al. The Effect of Brown Seaweed (Sargassum sp.) Extract on Apoptosis Process in Breast Cancer – A Literature Review , 2021, Indian Journal of Forensic Medicine & Toxicology.
[24] Prachi Mishra,et al. The Role of Tumor Necrosis Factor in Manipulating the Immunological Response of Tumor Microenvironment , 2021, Frontiers in Immunology.
[25] S. Varambally,et al. Comparative analysis of triple-negative breast cancer transcriptomics of Kenyan, African American and Caucasian Women , 2021, Translational oncology.
[26] Hongmin Li,et al. Pyruvate dehydrogenase kinases (PDKs): an overview toward clinical applications , 2021, Bioscience reports.
[27] K. Michalska,et al. Clinical significance of HRAS and KRAS genes expression in patients with non–small-cell lung cancer - preliminary findings , 2021, BMC cancer.
[28] M. Greabu,et al. PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects , 2020, International journal of molecular sciences.
[29] L. Kenner,et al. The Implications of PDK1–4 on Tumor Energy Metabolism, Aggressiveness and Therapy Resistance , 2020, Frontiers in Oncology.
[30] B. Chénais,et al. Fucoxanthin, a Marine-Derived Carotenoid from Brown Seaweeds and Microalgae: A Promising Bioactive Compound for Cancer Therapy , 2020, International journal of molecular sciences.
[31] Ana-Teresa Maia,et al. Differential expression between African-ancestry and White patients diagnosed with Triple-Negative Breast Cancer: EGFR, Myc, Bcl2 and β-Catenin as ancestry-associated markers , 2020, bioRxiv.
[32] P. Sun,et al. Role of RASA1 in cancer: A review and update , 2020, Oncology reports.
[33] Kang Yang,et al. Fucoxanthin may inhibit cervical cancer cell proliferation via downregulation of HIST1H3D , 2020, The Journal of international medical research.
[34] Hui Chen,et al. Fucoxanthin extracted from Laminaria Japonica inhibits metastasis and enhances the sensitivity of lung cancer to Gefitinib. , 2020, Journal of ethnopharmacology.
[35] J. Haybaeck,et al. Impact of Eukaryotic Translation Initiation Factors on Breast Cancer: Still Much to Investigate , 2020, Cancers.
[36] X. Bian,et al. Triple-negative breast cancer molecular subtyping and treatment progress , 2020, Breast Cancer Research.
[37] M. Mercogliano,et al. Tumor Necrosis Factor α Blockade: An Opportunity to Tackle Breast Cancer , 2020, Frontiers in Oncology.
[38] Jason B. White,et al. Identification of Distinct Heterogenic Subtypes and Molecular Signatures Associated with African Ancestry in Triple Negative Breast Cancer Using Quantified Genetic Ancestry Models in Admixed Race Populations , 2020, Cancers.
[39] A. Chinnathambi,et al. Fucoxanthin inhibits cell proliferation and stimulates apoptosis through downregulation of PI3K/AKT/mTOR signaling pathway in human ovarian cancer cells , 2020 .
[40] J. Buján,et al. Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR , 2020, Journal of oncology.
[41] Hailin Tang,et al. CircAHNAK1 inhibits proliferation and metastasis of triple-negative breast cancer by modulating miR-421 and RASA1 , 2019, Aging.
[42] M. Galiè. RAS as Supporting Actor in Breast Cancer , 2019, Front. Oncol..
[43] G. Hoxhaj,et al. The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism , 2019, Nature Reviews Cancer.
[44] V. Jain,et al. PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges. , 2019, Drug discovery today.
[45] T. Fehm,et al. Clinical relevance of H-RAS, K-RAS, and N-RAS mRNA expression in primary breast cancer patients , 2019, Breast Cancer Research and Treatment.
[46] K. Arunkumar,et al. Fucoxanthin , 2019, Biochemical and Environmental Bioprocessing.
[47] H. Farhan,et al. Multifaceted Rho GTPase Signaling at the Endomembranes , 2019, Front. Cell Dev. Biol..
[48] N. Tsuchida,et al. RAS Mutations in Human Cancers: Roles in Precision Medicine. , 2019, Seminars in cancer biology.
[49] Stephen P. Ethier,et al. Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer , 2019, BMC Cancer.
[50] M. Pellegrino,et al. Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells , 2019, Journal of Experimental & Clinical Cancer Research.
[51] L. Pusztai,et al. Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women , 2019, Breast Cancer Research and Treatment.
[52] W. Xiang,et al. Induction of Apoptosis in Human Glioma Cells by Fucoxanthin via Triggering of ROS-Mediated Oxidative Damage and Regulation of MAPKs and PI3K-AKT Pathways. , 2019, Journal of agricultural and food chemistry.
[53] Linlin Sui,et al. Fucoxanthin inhibits tumour‐related lymphangiogenesis and growth of breast cancer , 2019, Journal of cellular and molecular medicine.
[54] Min Song,et al. Mechanistic insight into activation of MAPK signaling by pro-angiogenic factors , 2018, BMC Systems Biology.
[55] Q. Peng,et al. The Akt pathway in oncology therapy and beyond (Review) , 2018, International journal of oncology.
[56] C. Zou,et al. CADM2, as a new target of miR-10b, promotes tumor metastasis through FAK/AKT pathway in hepatocellular carcinoma , 2018, Journal of experimental & clinical cancer research : CR.
[57] R. García-Becerra,et al. Preclinical and clinical aspects of TNF-α and its receptors TNFR1 and TNFR2 in breast cancer , 2017, Journal of Biomedical Science.
[58] E. Lam,et al. The FOXO3-FOXM1 axis: A key cancer drug target and a modulator of cancer drug resistance , 2017, Seminars in cancer biology.
[59] Xiao Meng,et al. Dietary Natural Products for Prevention and Treatment of Breast Cancer , 2017, Nutrients.
[60] Y. Satomi. Antitumor and Cancer-preventative Function of Fucoxanthin: A Marine Carotenoid. , 2017, Anticancer research.
[61] Debarshi Kar Mahapatra,et al. Triggering PIK3CA Mutations in PI3K/Akt/mTOR Axis: Exploration of Newer Inhibitors and Rational Preventive Strategies. , 2016, Current pharmaceutical design.
[62] Yugang Liu,et al. Fucoxanthin Activates Apoptosis via Inhibition of PI3K/Akt/mTOR Pathway and Suppresses Invasion and Migration by Restriction of p38-MMP-2/9 Pathway in Human Glioblastoma Cells , 2016, Neurochemical Research.
[63] Luc J. Martin. Fucoxanthin and Its Metabolite Fucoxanthinol in Cancer Prevention and Treatment , 2015, Marine drugs.
[64] H. El-Hadaad,et al. Current approaches in treatment of triple-negative breast cancer , 2015, Cancer biology & medicine.
[65] Yibo Tang,et al. Fucoxanthin: A Promising Medicinal and Nutritional Ingredient , 2015, Evidence-based complementary and alternative medicine : eCAM.
[66] K. Dahlman-Wright,et al. AP-1-mediated chromatin looping regulates ZEB2 transcription: new insights into TNFα-induced epithelial–mesenchymal transition in triple-negative breast cancer , 2015, Oncotarget.
[67] Jin-hai Tang,et al. Regulation of the cell cycle and PI3K/Akt/mTOR signaling pathway by tanshinone I in human breast cancer cell lines , 2014, Molecular medicine reports.
[68] Julie M. Madden,et al. Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer , 2014, Breast Cancer Research and Treatment.
[69] C. Porta,et al. Targeting PI3K/Akt/mTOR Signaling in Cancer , 2014, Front. Oncol..
[70] K. Miyashita,et al. Fucoxanthin: A Marine Carotenoid Exerting Anti-Cancer Effects by Affecting Multiple Mechanisms , 2013, Marine drugs.
[71] Kaleigh Fernald,et al. Evading apoptosis in cancer. , 2013, Trends in cell biology.
[72] C. Kingsley,et al. IRS1 is highly expressed in localized breast tumors and regulates the sensitivity of breast cancer cells to chemotherapy, while IRS2 is highly expressed in invasive breast tumors. , 2013, Cancer letters.
[73] C. Piyathilake,et al. Triple Negative Breast Cancer – An Overview , 2012, Hereditary genetics : current research.
[74] B. Hemmings,et al. PI3K-PKB/Akt pathway. , 2012, Cold Spring Harbor perspectives in biology.
[75] Andrew D. Sharrocks,et al. ELK1 Uses Different DNA Binding Modes to Regulate Functionally Distinct Classes of Target Genes , 2012, PLoS genetics.
[76] Mingli Liu,et al. The emerging role of CXCL10 in cancer (Review). , 2011, Oncology letters.
[77] K. Miyashita,et al. Effect of brown seaweed lipids on fatty acid composition and lipid hydroperoxide levels of mouse liver. , 2011, Journal of agricultural and food chemistry.
[78] N. Sonenberg,et al. eIF4B controls survival and proliferation and is regulated by proto-oncogenic signaling pathways , 2010, Cell cycle.
[79] Patrick Mayeux,et al. Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia , 2010, Haematologica.
[80] W. Link,et al. Understanding FOXO, new views on old transcription factors. , 2010, Current cancer drug targets.
[81] J. Prat,et al. Expression profiling of 22 genes involved in the PI3K–AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations , 2010, Modern Pathology.
[82] C. Gardana,et al. Toxicity and antioxidant activity in vitro and in vivo of two Fucus vesiculosus extracts. , 2008, Journal of agricultural and food chemistry.
[83] D. Tindall,et al. FOXOs, cancer and regulation of apoptosis , 2008, Oncogene.
[84] I. Frahm,et al. TNFα acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-κB-dependent pathways , 2008 .
[85] N. Ahmad,et al. RNA interference-mediated depletion of phosphoinositide 3-kinase activates forkhead box class O transcription factors and induces cell cycle arrest and apoptosis in breast carcinoma cells. , 2006, Cancer research.
[86] A. Toker,et al. Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. , 2005, Molecular cell.
[87] Enrique Casado,et al. PI3K/Akt signalling pathway and cancer. , 2004, Cancer treatment reviews.
[88] F. Alenzi,et al. Links between apoptosis, proliferation and the cell cycle , 2004, British journal of biomedical science.
[89] Daniel R. Caffrey,et al. LPS-TLR4 Signaling to IRF-3/7 and NF-κB Involves the Toll Adapters TRAM and TRIF , 2003, The Journal of experimental medicine.
[90] H. Shu,et al. TIRP, a Novel Toll/Interleukin-1 receptor (TIR) Domain-containing Adapter Protein Involved in TIR Signaling* , 2003, Journal of Biological Chemistry.
[91] A. Hall,et al. Rho GTPases in cell biology , 2002, Nature.
[92] A. Bresnick,et al. Roles of Rho-associated Kinase and Myosin Light Chain Kinase in Morphological and Migratory Defects of Focal Adhesion Kinase-null Cells* , 2002, The Journal of Biological Chemistry.
[93] A. Sharrocks,et al. The ETS Domain Transcription Factor Elk-1 Contains a Novel Class of Repression Domain , 2002, Molecular and Cellular Biology.
[94] Huitu Liu,et al. MAPK signal pathways in the regulation of cell proliferation in mammalian cells , 2002, Cell Research.
[95] Y. Sugiyama,et al. Vitamin A-related compounds, all-trans retinal and retinoic acids, selectively inhibit activities of mammalian replicative DNA polymerases. , 2002, Biochimica et biophysica acta.
[96] K. Miyashita,et al. Carotenoids affect proliferation of human prostate cancer cells. , 2001, The Journal of nutrition.
[97] P. Tsichlis,et al. PDK2: A Complex Tail in One Akt , 2001, Science's STKE.
[98] M. Kasten,et al. Cell cycle and apoptosis. , 2000, Neoplasia.
[99] H. Nishino,et al. Cancer prevention by carotenoids. , 1998, Mutation research.
[100] E. G. Nabel,et al. NATIONAL CANCER INSTITUTE , 1993, Definitions.
[101] N. Sonenberg,et al. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap , 1990, Nature.
[102] I. Frahm,et al. TNF alpha acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-kappa B-dependent pathways. , 2008, Experimental cell research.
[103] R. Assoian,et al. Cell anchorage and the cytoskeleton as partners in growth factor dependent cell cycle progression. , 1997, Current opinion in cell biology.